Understanding the Development Journey of Reta Peptide
Understanding Retatrutide Retatrutide is an investigational medication being developed by Eli Lilly as a once-weekly triple hormone receptor agonist. It targets GIP, GLP-1, and glucagon receptors and is being studied for obesity, type 2 diabetes, and other metabolic conditions. Although clinical research has produced encouraging results, retatrutide has not yet received approval from the FDA…